Journal of Clinical Pathways’ Post

Zolbetuximab's efficacy in targeting CLDN18.2 and addressing the unmet medical need in metastatic gastric or GEJ adenocarcinoma has been validated. The GLOW study underscores that zolbetuximab alongside chemotherapy sets a new standard of care for CLDN18.2-positive, HER2-negative cases of the disease. #MedicalBreakthrough #GastricCancer #HealthcareInnovation

Iovance Biotherapeutics has achieved a groundbreaking milestone in cancer therapy with the FDA's accelerated approval of Amtagvi, or lifileucel, the first CAR-T cell therapy designed specifically for solid tumors. This pioneering treatment, priced at $515,000, is tailored for advanced melanoma patients who have exhausted options with a PD-1 inhibitor and, where applicable, a BRAF inhibitor for BRAF V600 mutation. Amtagvi's approval heralds a new era in oncology, extending the benefits of CAR-T cell therapy—previously confined to blood cancers—to solid tumors for the first time. Produced from a patient's own tumor-infiltrating lymphocytes (TIL), Amtagvi leverages the body's innate cancer-fighting capabilities, demonstrating a notable 31.5% tumor reduction rate in crucial trials. Despite its significant cost and the need for close monitoring in a hospital setting due to potential severe side effects, Amtagvi's introduction marks a significant advancement in personalized cancer treatment, offering renewed hope to patients with advanced melanoma. #cartcelltherapy #solidtumor

New research reveals immunotherapy is improving survival for people with advanced #NSCLC. 👉 Improvements seen in 1-year, 3-year and 5-year OS rates 👉 1 in 10 patients now living past 5 years 👉 5-year survival rate nearly doubled from 6.8% to 10.7% Read more about the study here: https://bit.ly/4h7Y6ZP #LungCancer #Immunotherapy #CancerResearch

Nice and quick read on some of the key highlights from #SGO2024… immunotherapy, ADCs, PARPs, and more!

CU Cancer Center leader Christopher Lieu, MD, discusses how immunotherapy has changed the landscape for the treatment of metastatic hepatocellular carcinoma with Namrata Vijayvergia, MD, of Fox Chase Cancer Center. Watch the discussion here: https://bit.ly/3vI0zXY #Carcinoma #Immunotherapy #CancerTreatment

#Digitalhealth monitoring company Elekta has teamed up with US #pharmaceutical giant Merck & Co to develop a #patient monitoring system for individuals diagnosed with renal cell carcinoma (RCC). This collaborative effort aims to create a digital module offering comprehensive #symptom monitoring and #patient support, allowing RCC patients to stay connected with their #healthcare team and access information about their condition, treatment, and potential side effects. The partners plan to validate the module later this year in collaboration with several leading #cancer clinics in Europe. Leveraging Elekta's Kaiku Health #digital platform, the solution focuses on patient engagement and outcomes monitoring, with the goal of providing structured support for symptom management and #educating patients about their disease and treatment. Read the article to find out more: https://lnkd.in/eHg5dfYX

📢 Today is World Rare Disease Day and we're thrilled to announce that we've received 1.3M euro grant from the Agencia Estatal de Investigación to advance to clinical phase a new promising CAR T therapy for T-ALL, a rare and aggressive form of leukemia affecting children and adults with limited treatment options. This groundbreaking project, in collaboration with the Josep Carreras Leukaemia Research Institute and the Banc de Sang i Teixits, leverages CAR T technology to offer new hope to up to 80% of T-ALL patients, significantly expanding the potential treatment pool beyond the limitations of current therapies. 🏥 This therapeutic approach builds on the success of a previous therapy developed by the same company, which is currently being evaluated in the #CARxALL Phase 1 clinical trial. Read all the info here 👉 https://lnkd.in/dnRg_Tij #RareDiseaseDay #LightUpForRare #CARTTherapy #Healthcare #LeukemiaTreatment

#WorldCMLDay. When something as simple as taking your medications as prescribed extends life, we do everything possible to make sure that gets done. Honoring World CML Day respects the advances in research and promotes the vital role that medication adherence plays in the treatment of chronic myeloid leukemia (CML), especially with the use of life-saving tyrosine kinase inhibitors (TKIs). A recent study, “Adherence to Tyrosine Kinase Inhibitors and Clinical Outcomes in Patients with Chronic Myeloid Leukemia,” utilized the Morisky Medication Adherence Scale (MMAS) to identify patients at risk of non-adherence. The study found that those who scored lower on the MMAS were more likely to experience worse clinical outcomes, including disease progression and reduced survival rates. With this information, healthcare professionals can proactively intervene by using the MMAS to identify adherence challenges early and implement personalized strategies to support patients in staying on their prescribed TKI regimen. When the barriers to adherence are identified, we can improve patient outcomes and help those with CML achieve better long-term health.

Treatment Update: Are #cancer patients the best judges of whether they can tolerate their drug regimen? #Oncologists, what do you think? Let me know and share this with a colleague. "Multiple Myeloma Treatment Tolerability: Ask the Patients" By Bowery Consulting contributor, Brett Moskowitz "...a patient's overall experience of side effects, potentially reflecting the impact of multiple toxicities, is a good predictor of whether or not they will drop out of a trial for adverse events." John (Devin) Peipert, Northwestern University - The Feinberg School of Medicine https://lnkd.in/e2Y_ytdU Mary Desmond Pinkowish MedPage Today #multiplemyeloma

Results: #The_incidence_of_FN was #significantly #lower in the pegfilgrastim group (42.9%) than in the filgrastim group (69.6%), p<0.004. The mean number of #hospital_visits was 1.84+1.93 in the filgrastim group and 0.84+1.19 in the pegfilgrastim group with 58.90% and 33.9% hospital admission, respectively. The mean #duration_of_stay was 4.1429+3.69 days in the filgrastim group and 2.36+3.35 days in the pegfilgrastim group. The total mean cost (Nepali rupees) of filgrastim and pegfilgrastim was 20162.50+6645.37 and 32210.71+10429.43, respectively. Conclusions: #A_single_dose of #pegfilgrastim is #better_than #multiple #doses of filgrastim in #reducing_FN_incidence which #minimizes_hospital_stay, visits, and frequency of admission in cancer patients receiving chemotherapy. taken together, the adequate evaluation of patients and the use of prophylactic GCSFs become relevant for optimizing clinical outcomes and reducing hospitalization-related morbidities in the #management_of_FN.